Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis

Drug Discovery Today

Volumn 19, Issue 8, 2014, Pages 1200-1204

  Whang, Jennifer A ^a   Chang, Betty Y ^a  

^a PHARMACYCLICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRUTON TYROSINE KINASE INHIBITOR; CC 292; FC RECEPTOR; GD 0834; IBRUTINIB; PRE B CELL RECEPTOR; UNCLASSIFIED DRUG; AGAMMAGLOBULINAEMIA TYROSINE KINASE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

B LYMPHOCYTE ACTIVATION; BONE MARROW CELL; CELL MATURATION; CELL POPULATION; CYTOKINE PRODUCTION; HUMAN; MACROPHAGE; MAST CELL; MONOCYTE; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; B LYMPHOCYTE; DRUG EFFECTS; IMMUNOLOGY;

ANIMALS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; HUMANS; PRE-B CELL RECEPTORS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 84906324615     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.03.028     Document Type: Review

References (41)

1. J. Jongstra-Bilen et al. Dual functions of Bruton's tyrosine kinase and Tec kinase during Fcgamma receptor-induced signaling and phagocytosis J. Immunol. 181 2008 288 298
2. D. Hata et al. Involvement of Bruton's tyrosine kinase in FcepsilonRI-dependent mast cell degranulation and cytokine production J. Exp. Med. 187 1998 1235 1247
3. L. Jansson, and R. Holmdahl Genes on the X chromosome affect development of collagen-induced arthritis in mice Clin. Exp. Immunol. 94 1993 459 465
4. I.B. McInnes, and G. Schett The pathogenesis of rheumatoid arthritis N. Engl. J. Med. 365 2011 2205 2219
5. G.R. Burmester et al. Emerging cell and cytokine targets in rheumatoid arthritis Nat. Rev. Rheumatol. 2013
6. J.D. Isaacs Therapeutic T-cell manipulation in rheumatoid arthritis: past, present and future Rheumatology 47 2008 1461 1468
7. J.C. Edwards et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis N. Engl. J. Med. 350 2004 2572 2581
8. L. Svensson et al. B cell-deficient mice do not develop type II collagen-induced arthritis (CIA) Clin. Exp. Immunol. 111 1998 521 526
9. P. Emery et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial Arthritis Rheum. 54 2006 1390 1400
10. S.B. Cohen et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks Arthritis Rheum. 54 2006 2793 2806
11. J.C. Edwards, and G. Cambridge Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes Rheumatology 40 2001 205 211
12. R.R. Hardy, and K. Hayakawa B cell development pathways Annu. Rev. Immunol. 19 2001 595 621
13. K.P. Lam et al. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death Cell 90 1997 1073 1083
14. M.H. Levine et al. A B-cell receptor-specific selection step governs immature to mature B cell differentiation Proc. Natl. Acad. Sci. U. S. A. 97 2000 2743 2748
15. A.B. Satterthwaite et al. Btk function in B cell development and response Semin. Immunol. 10 1998 309 316
16. W.N. Khan Regulation of B lymphocyte development and activation by Bruton's tyrosine kinase Immunol. Res. 23 2001 147 156
17. A.J. Mohamed et al. Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain Immunol. Rev. 228 2009 58 73
18. S. Tsukada et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia Cell 72 1993 279 290
19. D.J. Rawlings et al. Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice Science 261 1993 358 361
20. W.N. Khan et al. Defective B cell development and function in Btk-deficient mice Immunity 3 1995 283 299
21. J.D. Kerner et al. Impaired expansion of mouse B cell progenitors lacking Btk Immunity 3 1995 301 312
22. L.P. Kil et al. Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice Blood 119 2012 3744 3756
23. T. Takai Roles of Fc receptors in autoimmunity Nat. Rev. Immunol. 2 2002 580 592
24. T. Yuasa et al. Deletion of fcgamma receptor IIB renders H-2(b) mice susceptible to collagen-induced arthritis J. Exp. Med. 189 1999 187 194
25. S. Kleinau et al. Induction and suppression of collagen-induced arthritis is dependent on distinct fcgamma receptors J. Exp. Med. 191 2000 1611 1616
26. T. Kagari et al. Essential role of Fc gamma receptors in anti-type II collagen antibody-induced arthritis J. Immunol. 170 2003 4318 4324
27. S. Kleinau et al. Importance of CD23 for collagen-induced arthritis: delayed onset and reduced severity in CD23-deficient mice J. Immunol. 162 1999 4266 4270
28. Z. Pan et al. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase ChemMedChem 2 2007 58 61
29. L. Liu et al. Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy J. Pharmacol. Exp. Ther. 338 2011 154 163
30. E.K. Evans et al. Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans J. Pharmacol. Exp. Ther. 346 2013 219 228
31. M. Labenski et al. In vitro reactivity assessment of covalent drugs targeting Bruton's tyrosine kinase Drug Metab. Rev. 43 2011 140 141
32. K.H. Kim et al. Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis Bioorg. Med. Chem. Lett. 21 2011 6258 6263
33. L.A. Honigberg et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy Proc. Natl. Acad. Sci. U. S. A. 107 2010 13075 13080
34. J.A. Di Paolo et al. Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis Nat. Chem. Biol. 7 2011 41 50
35. D. Xu et al. RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents J. Pharmacol. Exp. Ther. 341 2012 90 103
36. T. Yoshizawa et al. Development of a Bruton's tyrosine kinase (Btk) inhibitor, ONO-4059: efficacy in a collagen induced arthritis (CIA) model indicates potential treatment for rheumatoid arthritis (RA) Arthritis Rheum. 64 2012 S709
37. B.Y. Chang et al. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells Arthritis Res. Ther. 13 2011 R115
38. L. Liu et al. Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton's tyrosine kinase inhibitor Drug Metab. Dispos. 39 2011 1840 1849
39. A. Akinleye et al. Ibrutinib and novel BTK inhibitors in clinical development J. Hematol. Oncol. 6 2013 59
40. J. Hutcheson et al. Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus Arthritis Res. Ther. 14 2012 R243
41. A.L. Rankin et al. Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis J. Immunol. 191 2013 4540 4550